Document:

ex-107for10xqfilingxform

8-15-2022 SEAGEN INC.  FRENCH-QUALIFIED RESTRICTED STOCK UNIT GRANT NOTICE Seagen Inc. (the “Company”), pursuant to its Amended and Restated 2007 Equity Incentive Plan (the “U.S. Plan”)  and the Rules of the Seagen Inc. Amended and Restated 2007 Equity Incentive Plan for Stock Units granted to French  Grantees (the “French RSU Sub-Plan;” together with the U.S. Plan, the “Plan”), hereby awards to Grantee a Stock  Unit Award for the number of stock units set forth below (the “Award”).  The Award is subject to all of the terms and  conditions as set forth herein and in the Plan and the French-Qualified Restricted Stock Unit Agreement for Grantees  in France (the “Agreement”).  Capitalized terms not otherwise defined herein shall have the meanings set forth in the  Plan or the Agreement, as applicable. Except as otherwise explicitly provided herein, in the event of any conflict  between the terms in the Award and the Plan, the terms of the Plan shall control.  Grantee: [•]  Date of Grant: [•]  Vesting Commencement Date: [•]  Number of French-Qualified   Restricted Stock Units   Subject to Award: [•]  Vesting Schedule:  Subject to Section 3 of the Agreement, this Award shall vest on the below vesting  date(s). Notwithstanding the foregoing, vesting shall terminate upon the Grantee’s  Termination of Employment.  [•] Consideration: Grantee’s services  Issuance Schedule: The Shares to be issued in respect of the Award will be issued in accordance with the  issuance schedule set forth in Section 8 of the Agreement.  Sell to Cover Election: By accepting this Award, Grantee hereby: (1) elects, effective on the date Grantee  accepts this Award, to sell Shares issued in respect of the Award in an amount  determined in accordance with Section 13(c) of the Agreement, and to allow the Agent  to remit the cash proceeds of such sale to the Company as more specifically set forth in  Section 13(c) of the Agreement (a “Sell to Cover”); (2) directs the Company to make a  cash payment to satisfy the Withholding Obligation from the cash proceeds of such sale  directly to the appropriate taxing authorities; and (3) represents and warrants that (i)  Grantee has carefully reviewed Section 13(c) of the Agreement, (ii) Participant is  not aware of any material, nonpublic information with respect to the Company or  any securities of the Company as of the Date of Grant, provided that if Participant  is in possession of such material, nonpublic information as of the Date of Grant,  then the mandatory sale of Shares pursuant to Section 13(c) of the Global Stock  Unit Agreement shall become a binding contract as of the first date thereafter on  which Participant is not in possession of material, nonpublic information and  Participant shall not effect any sales pursuant to Section 13(c) on the basis of  material, nonpublic information of which Participant was aware of on the Date of  Grant, (iii) on the date Participant accepts this Award Participant is not subject to  any legal, regulatory or contractual restriction that would prevent the Agent from  conducting sales, does not have, and will not attempt to exercise, authority,  influence or control over any sales of Shares effected by the Agent pursuant to the  Agreement, and is entering into the Agreement and this election to Sell to Cover in  good faith and not as part of a plan or scheme to evade the prohibitions of Rule  Exhibit 10.7 

 

    8-15-2022      10b5-1 (regarding trading of the Company's securities on the basis of material  nonpublic information) under the Exchange Act or other applicable securities laws,  and (iii) it is Grantee’s intent that this election to Sell to Cover and Section 13(c) of  the Agreement comply with the requirements of Rule 10b5-1(c)(1) under the  Exchange Act or other applicable securities laws and be interpreted to comply with  the requirements of Rule 10b5-1(c) under the Exchange Act or other applicable  securities laws. The Grantee further acknowledges that by accepting this Award,  Grantee is adopting a 10b5-1 Plan (as defined in Section 13(c) of the Agreement) to  permit Grantee to conduct a Sell to Cover sufficient to satisfy the Withholding  Obligation as more specifically set forth in Section 13(c) of the Agreement.  Additional Terms/Acknowledgements:  Grantee acknowledges receipt of, and understands and agrees to, this  French-Qualified Restricted Stock Unit Grant Notice, the Agreement (including the provisions of Section 13(c) thereof  with respect to the Sell to Cover) and the Plan.  Grantee also acknowledges receipt of the Prospectus for the Plan.   Grantee further acknowledges that as of the Date of Grant, this French-Qualified Restricted Stock Unit Grant Notice,  the Agreement and the Plan set forth the entire understanding between Grantee and the Company regarding the Award  and supersede all prior oral and written agreements on that subject, with the exception of any arrangement that would  provide for vesting acceleration of the Award upon the terms and conditions set forth therein.    Grantee’s electronic acceptance shall signify Grantee’s execution of this French-Qualified Restricted Stock Unit Grant  Notice and understanding that this Award is granted and governed under the terms and conditions set forth herein.     SEAGEN INC.            Jean I. Liu  Chief Legal Officer        **PLEASE PRINT AND RETAIN THIS AGREEMENT FOR YOUR RECORDS** 

 

     1.     8-15-2022        SEAGEN INC.  AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN    FRENCH-QUALIFIED RESTRICTED STOCK UNIT AGREEMENT  Pursuant to the French-Qualified Restricted Stock Unit Grant Notice (“Grant Notice”) and  this French-Qualified Restricted Stock Unit Agreement (this “Agreement”), Seagen Inc. (the  “Company”) has awarded you a French-Qualified Restricted Stock Unit Award (the “Award”)  under its Amended and Restated 2007 Equity Incentive Plan (the “U.S. Plan”) and the Rules of  the Seagen Inc. Amended and Restated 2007 Equity Incentive Plan for Stock Units granted to  French Grantees (the “French RSU Sub-Plan;” together with the U.S. Plan, the “Plan”). Your  Award is granted to you effective as of the Date of Grant set forth in the Grant Notice for this  Award.  This Agreement shall be deemed to be agreed to by the Company and you upon your  execution of the Grant Notice to which it is attached.  Capitalized terms not explicitly defined in  this Agreement shall have the same meanings given to them in the Plan or the Grant Notice, as  applicable.  Except as otherwise explicitly provided herein, in the event of any conflict between  the terms in this Agreement and the Plan, the terms of the Plan shall control.  The details of your  Award, in addition to those set forth in the Grant Notice and the Plan, are as follows.  1. GRANT OF THE AWARD.    This Award represents the right to be issued on a future  date the number of Shares that is equal to the number of stock units indicated in the Grant Notice  (the “French-Qualified RSUs”).  As of the Date of Grant, the Company will credit to a  bookkeeping account maintained by the Company for your benefit (the “Account”) the number of  French-Qualified RSUs subject to the Award.  This Award is granted in consideration of your  services to the Company or an Affiliate.  Except as otherwise provided herein, you will not be  required to make any payment to the Company (other than future services to the Company) with  respect to your receipt of the Award, the vesting of the French-Qualified RSUs or the delivery of  the Shares to be issued in respect of the Award.   2. FRENCH-QUALIFIED STATUS.  The Awards granted pursuant to this Agreement are  intended to qualify for the special tax and social security treatment in France applicable to rights  to shares granted for no consideration under Sections L. 225-197-1 to L. 225-197-6 of the French  Commercial Code, as amended.  However, certain events may affect the qualified status of the  Awards and the Company does not make any undertaking or representation to maintain the  qualified status of the Award.  If the Awards do not retain their qualified status, the special tax and  social security treatment will not apply and you will be required to pay your portion of social  security contributions resulting from the Award, as well as any income and other taxes that may  be due pursuant to other rules for non-qualified restricted stock units.   3. VESTING.    Subject to the limitations contained herein, your Award will vest, if at  all, in accordance with the vesting schedule provided in the Grant Notice, provided that you have  not incurred a Termination of Employment before the applicable vesting date set forth in the Grant  Notice. In no event shall any French-Qualified RSUs vest prior to the second anniversary of the  

 

     2.     8-15-2022        Vesting Commencement Date, or such other period as required to comply with the minimum  vesting period under Sections L. 225-197-1 of the French Commercial Code, as amended. Upon  your Termination of Employment, the French-Qualified RSUs credited to the Account that are not  vested on the date of such Termination of Employment will be forfeited at no cost to the Company  and you will have no further right, title or interest in the French-Qualified RSUs or the Shares to  be issued in respect of the Award.  By accepting the grant of this Award, you acknowledge and  agree that the terms set forth in this Section 3 supersede any contrary terms regarding the vesting  of this Award set forth in any notice or other communication that you receive from, or that is  displayed by, E*TRADE or other third party designated by the Company.  For purposes of your Award, your Termination of Employment will be considered to be  (regardless of the reason of termination, whether or not later found to be invalid or in breach of  employment or other laws or rules in the jurisdiction where you are providing services or the terms  of your employment or service agreement, if any) effective as of the date that you cease to actively  provide services to the Company or any Affiliate and will not be extended by any notice period  (e.g., employment or service would not include any contractual notice period or any period of  “garden leave” or similar period mandated under employment or other laws in the jurisdiction  where you are employed or providing services or the terms of your employment or service  agreement, if any). The Administrator shall have exclusive discretion to determine when you are  no longer actively employed or providing services for purposes of the Plan (including whether you  still may be considered to be providing services while on a leave of absence).    Notwithstanding the foregoing or anything in this Agreement to the contrary, in the event  of your Termination of Employment as a result of your death, the vesting of your Award shall  accelerate and become immediately transferable to your heirs and Shares will be issued to your  heirs upon their request for a period of six months following the date of your death; otherwise, the  French-Qualified RSUs will be forfeited at the end of the expiration of the six-month period.  Notwithstanding the foregoing or anything in this Agreement to the contrary, in the event  of your Termination of Employment as a result of your Disability, the vesting of your Award shall  accelerate such that your Award shall become vested as to an additional twelve (12) months,  effective as of the date of such Termination of Employment, to the extent that your Award is  outstanding on such date.   4. FORFEITURE OF AWARD NOT TIMELY ACCEPTED.  The Award is conditioned  upon your electronic acceptance of the Award, as set forth in the Grant Notice. Notwithstanding  the foregoing or anything in this Agreement to the contrary, if you fail to accept the Award prior  to the vesting dates set forth in the Grant Notice, the portion of the Award that otherwise would  have vested on each such date will be forfeited at no cost to the Company, and you will have no  further right, title or interest in such portion. In the event of your Termination of Employment as  

 

     3.     8-15-2022        a result of your death or Disability prior to acceptance of the Award, the Company will deem  the Award as being accepted.  5. NUMBER OF SHARES.   (a)  The number of French-Qualified RSUs subject to your Award may be  adjusted from time to time for changes in capitalization, as provided in Section 13 of the U.S. Plan.  (b) Any additional French-Qualified RSUs that become subject to the Award  pursuant to this Section 5 shall be subject, in a manner determined by the Administrator, to the  same forfeiture restrictions, restrictions on transferability, and time and manner of delivery as  applicable to the other French-Qualified RSUs covered by your Award.  (c) Notwithstanding the provisions of this Section 5, no fractional Shares or  rights for fractional Shares shall be created pursuant to this Section 5.  The Administrator shall, in  its discretion, determine an equivalent benefit for any fractional Shares or fractional Shares that  might be created by the adjustments referred to in this Section 5.  6. SECURITIES LAW COMPLIANCE.  You may not be issued any Shares in respect of  your Award unless either (i) such Shares are registered under the Securities Act or other applicable  securities laws; or (ii) the Company has determined that such issuance would be exempt from the  registration requirements of the Securities Act or other applicable securities laws. Your Award  also must comply with other applicable laws and regulations governing the Award, and you will  not receive such Shares if the Company determines that such receipt would not be in material  compliance with such laws and regulations. You represent and warrant that you (a) have been  furnished with a copy of the Plan and the prospectus for the Plan and all information deemed  necessary to evaluate the merits and risks of receipt of the Award, (b) have had the opportunity to  ask questions concerning the information received about the Award and the Company, and (c)  have been given the opportunity to obtain any information you deem necessary to verify the  accuracy of any information obtained concerning the Award and the Company.  7. TRANSFER RESTRICTIONS.  Your Award is not transferable, except by will or by  the applicable laws of descent and distribution.  In addition to any other limitation on transfer  created by applicable securities laws, you agree not to assign, hypothecate, donate, encumber or  otherwise dispose of any interest in any of the Shares subject to the Award until the Shares are  issued to you in accordance with Section 8 of this Agreement.  After such Shares have been issued  to you, you are free to assign, hypothecate, donate, encumber or otherwise dispose of any interest  in such Shares provided that any such actions are in compliance with the provisions herein and  applicable securities laws.   8. DATE OF ISSUANCE.    (a) If the Award is exempt from application of Section 409A of the Code and  any state law of similar effect (collectively “Section 409A”), then, subject to Section 13, the  Company will deliver to you a number of Shares equal to the number of vested French-Qualified  

 

     4.     8-15-2022        RSUs subject to your Award, including any additional French-Qualified RSUs received pursuant  to Section 5 above that relate to those vested French-Qualified RSUs on or within 60 days  following the applicable vesting date (the “Original Issuance Date”).  However, if the Original  Issuance Date falls on a date that is not a business day, such delivery date shall instead fall on the  next following business day.  Notwithstanding the foregoing, if (i) the Original Issuance Date does  not occur (1) during an “open window period” applicable to you, as determined by the Company  in accordance with the Company’s then-effective policy or policies on trading in Company  securities or (2) on a date when you are otherwise permitted to sell Shares on the open market; and  (ii) the Company elects, prior to the Original Issuance Date, (x) not to satisfy the Withholding  Obligation (as defined in Section 13(b) hereof) by withholding Shares from the Shares otherwise  due, on the Original Issuance Date, to you under this Award pursuant to Section 13 hereof, (y) not  to permit you to then effect a Sell to Cover under the 10b5-1 Plan (as defined in Section 13(c) of  this Agreement), and (z) not to permit you to satisfy the Withholding Obligation in cash, then such  Shares shall not be delivered on such Original Issuance Date and shall instead be delivered on the  first business day of the next occurring open window period applicable to you or the next business  day when you are not prohibited from selling Shares on the open market, as applicable (and  regardless of whether there has been a Termination of Employment before such time), but in no  event later than the 15th day of the third calendar month of the calendar year following the calendar  year in which the French-Qualified RSUs vest.  Delivery of the Shares pursuant to the provisions  of this Section 8(a) is intended to comply with the requirements for the short-term deferral  exemption available under Treasury Regulations Section 1.409A-1(b)(4) and shall be construed  and administered in such manner.  The form of such delivery of the Shares (e.g., a stock certificate  or electronic entry evidencing such Shares) shall be determined by the Company.  (b) The provisions of this Section 8(b) are intended to apply if the Award is  subject to Section 409A because of the terms of a severance arrangement or other agreement  between you and the Company, if any, that provide for acceleration of vesting of the Award upon  your separation from service (as such term is defined in Section 409A(a)(2)(A)(i) of the Code  (“Separation from Service”) and such severance benefit does not satisfy the requirements for an  exemption from application of Section 409A provided under Treasury Regulations Section  1.409A-1(b)(4) or 1.409A-1(b)(9) (“Non-Exempt Severance Arrangement”).  If the Award is  subject to and not exempt from application of Section 409A due to application of a Non-Exempt  Severance Arrangement, the following provisions in this Section 8(b) shall supersede anything to  the contrary in Section 8(a).    (i) If the Award vests in the ordinary course before your Termination  of Employment in accordance with the vesting schedule set forth in the Grant Notice, without  accelerating vesting under the terms of a Non-Exempt Severance Arrangement, in no event will  the Shares to be issued in respect of your Award be issued any later than December 31st of the  calendar year that includes the applicable vesting date.    (ii) If vesting of the Award accelerates under the terms of a Non-Exempt  Severance Arrangement in connection with your Separation from Service, and such vesting  acceleration provisions  were in effect as of the date of grant of the Award and, therefore, are part  of the terms of the Award as of the date of grant, then the Shares will be earlier issued in respect  

 

     5.     8-15-2022        of your Award upon your Separation from Service in accordance with the terms of the Non-Exempt  Severance Arrangement, but in no event later than the 60th day that follows the date of your  Separation from Service.  However, if at the time the Shares would otherwise be issued you are  subject to the distribution limitations contained in Section 409A applicable to “specified  employees,” as defined in Section 409A(a)(2)(B)(i) of the Code, such Shares shall instead be  issued on the date that is six months following the date of your Separation from Service, or, if  earlier, the date of your death that occurs within such six-month period.  (iii) If  either (A) vesting of the Award accelerates under the terms of a  Non-Exempt Severance Arrangement in connection with your Separation from Service, and such  vesting acceleration provisions were not in effect as of the date of grant of the Award and,  therefore, are not a part of the terms of the Award on the date of grant, or (B) vesting accelerates  pursuant to Section 4(b) or Section 13 of the U.S. Plan, then such acceleration of vesting of the  Award shall not accelerate the issuance date of the Shares (or any substitute property), but such  Shares (or substitute property) shall instead be issued on the same schedule as set forth in the Grant  Notice as if they had vested in the ordinary course before your Termination of Employment,  notwithstanding the vesting acceleration of the Award.  Such issuance schedule is intended to  satisfy the requirements of payment on a specified date or pursuant to a fixed schedule, as provided  under Treasury Regulations Section 1.409A-3(a)(4).  (c) Notwithstanding anything to the contrary set forth herein, the Company  explicitly reserves the right to earlier issue the Shares in respect of the Award to the extent  permitted and in compliance with the requirements of Section 409A, including pursuant to any of  the exemptions available in Treasury Regulations Section 1.409A-3(j)(4)(ix).  (d) The provisions in this Agreement for delivery of the Shares in respect of the  Award are intended either to comply with the requirements of Section 409A or to provide a basis  for exemption from such requirements so that the vesting or delivery of such Shares will not trigger  the additional tax imposed under Section 409A, and any ambiguities herein will be so interpreted.  (e) The Administrator may modify the terms of this Agreement and/or the Plan  without your consent, in the manner that the Administrator may determine to be necessary or  advisable in order to comply with Code Section 409A or to mitigate any additional tax, interest  and/or penalties or other adverse tax consequences that may apply under Code Section 409A if  compliance is not practical. This Section 8(e) does not create an obligation on the part of the  Company to modify the terms of this Agreement or the Plan and does not guarantee that this Award  or the delivery of Shares upon settlement of the Award will not be subject to taxes, interest and  penalties or any other adverse tax consequences under Code Section 409A. Nothing in this  Agreement shall provide a basis for any person to take any action against the Company or any of  its Subsidiaries or Affiliates based on matters covered by Code Section 409A, including the tax  treatment of any amounts paid under this Agreement, and neither the Company nor any of its  Subsidiaries or Affiliates will have any liability under any circumstances to the Participant or any  other party if the Award, the delivery of Shares upon vesting/settlement of the Award or other  payment or tax event hereunder that is intended to be exempt from, or compliant with, Code  

 

     6.     8-15-2022        Section 409A, is not so exempt or compliant or for any action taken by the Administrator with  respect thereto.  9. DIVIDENDS.   You shall receive no benefit or adjustment to your Award with respect  to any cash dividend, stock dividend or other distribution that does not result from a change in  capitalization as provided in Section 13 of the U.S. Plan; provided, however, that this sentence  shall not apply with respect to any Shares that are delivered to you in connection with your Award  after such Shares have been delivered to you.  10. RESTRICTIVE LEGENDS.  The Shares issued in respect of your Award shall be  endorsed with appropriate legends determined by the Company.  11. AWARD NOT A SERVICE CONTRACT.    (a) Nothing in this Agreement (including, but not limited to, the vesting of your  Award pursuant to the schedule set forth in Section 3 herein or the issuance of the Shares in respect  of your Award), the Plan or any covenant of good faith and fair dealing that may be found implicit  in this Agreement or the Plan shall:  (i) confer upon you any right to continue in the employ of, or  affiliation with, the Company or an Affiliate; (ii) constitute any promise or commitment by the  Company or an Affiliate regarding the fact or nature of future positions, future work assignments,  future compensation or any other term or condition of employment or affiliation; (iii) confer any  right or benefit under this Agreement or the Plan unless such right or benefit has specifically  accrued under the terms of this Agreement or Plan; or (iv) deprive the Company or an Affiliate of  the right to terminate your employment without regard to any future vesting opportunity that you  may have.  (b) By accepting this Award, you acknowledge and agree that the right to  continue vesting in the Award pursuant to the schedule set forth in Section 3 is earned only by  continuing as an employee, director or consultant of the Company or Affiliate, as applicable (not  through the act of being hired, being granted this Award or any other award or benefit) and that  the Company has the right to reorganize, sell, spin-out or otherwise restructure one or more of its  businesses or Affiliates at any time or from time to time, as it deems appropriate (a  “reorganization”).  You further acknowledge and agree that such a reorganization could result in  your Termination of Employment, or the termination of Affiliate status of your employer and the  loss of benefits available to you under this Agreement, including but not limited to, the termination  of the right to continue vesting in the Award.  You further acknowledge and agree that this  Agreement, the Plan, the transactions contemplated hereunder and the vesting schedule set forth  herein or any covenant of good faith and fair dealing that may be found implicit in any of them do  not constitute an express or implied promise of continued engagement as an employee or  consultant for the term of this Agreement, for any period, or at all, and shall not interfere in any  way with your right or the right of the Company or its Affiliate to terminate your service at any  time, with or without cause and with or without notice.  

 

     7.     8-15-2022        12. NATURE OF AWARD.  In accepting your Award, you acknowledge, understand and  agree that:  (a) the Plan is established voluntarily by the Company, it is discretionary in  nature and it may be modified, amended, suspended or terminated by the Company at any time, to  the extent permitted under the Plan;  (b) the Award is exceptional, voluntary and occasional and does not create any  contractual or other right to receive future Awards (whether on the same or different terms), or  benefits in lieu of an Award, even if an Award has been granted in the past;  (c) all decisions with respect to future awards of French-Qualified RSUs or  other grants, if any, will be at the sole discretion of the Company;  (d) you are voluntarily participating in the Plan;  (e) the Award and any Shares acquired under the Plan, and the income from  and value of same, are not intended to replace any pension rights or compensation;  (f) the future value of the Shares underlying the Award is unknown,  indeterminable and cannot be predicted with certainty;  (g) no claim or entitlement to compensation or damages shall arise from  forfeiture of the Award resulting from your Termination of Employment (for any reason  whatsoever whether or not later found to be invalid or in breach of employment laws in the  jurisdiction where you are employed or rendering services or the terms of your employment  agreement, if any);  (h) unless otherwise provided herein, in the Plan or by the Company in its  discretion, the Award and the benefits evidenced by this Agreement do not create any entitlement  to have the Award or any such benefits transferred to, or assumed by, another company nor to be  exchanged, cashed out or substituted for, in connection with any corporate transaction affecting  the Shares;  (i) unless otherwise agreed with the Company, the Award and the Shares  subject to the Award, and the income from and value of same, are not granted as consideration for,  or in connection with, the service you may provide as a director of an Affiliate;   (j) if the Award vests and you are issued Shares, the value of such Shares may  increase or decrease in value following the date the Shares are issued; even below the Fair Market  Value on the date the Award is granted to you;  (k) the Award and the Shares subject to the Award, and the income and value  of same, are not part of normal or expected compensation for any purpose, including, without  limitation, calculating any severance, resignation, termination, redundancy, dismissal, end-of- 

 

     8.     8-15-2022        service payments, bonuses, holiday pay, long-service awards, pension or retirement or welfare  benefits or similar payments; and  (l) the Award and the Shares subject to the Award, and the income and value  of same, shall not be included as compensation, earnings, salaries, or other similar terms used  when calculating your benefits under any benefit plan sponsored by the Company, except as such  plan otherwise expressly provides. The Company expressly reserves its rights to amend, modify,  or terminate any of the Company’s benefit plans.  13. TAX OBLIGATIONS.  (a) By accepting this Award, you acknowledge that, regardless of any action  taken by the Company or any Affiliate the ultimate liability for any and all income tax, social  insurance, payroll tax, fringe benefit tax, payment on account or other tax-related items related to  your participation in the Plan and legally applicable to you (“Tax-Related Items”) is and remains  your responsibility and may exceed the amount actually withheld by the Company or its Affiliates,  if any. Further, if you are subject to Tax-Related Items in more than one jurisdiction, you  acknowledge that the Company and/or its Affiliates may be required to withhold or account for  Tax-Related Items in more than one jurisdiction.  The Company has no duty or obligation to  minimize the tax consequences to you of this Award and shall not be liable to you for any adverse  tax consequences to you arising in connection with this Award.   (b) On or before the time you receive a distribution of Shares pursuant to your  Award, or at any time thereafter as requested by the Company, you hereby authorize any required  withholding from the Shares issuable to you and/or otherwise agree to make adequate provision in  cash for any sums required to satisfy any and all Tax-Related Items (the “Withholding  Obligation”).    (c) By accepting this Award, you hereby (i) acknowledge and agree that you  have elected a Sell to Cover (as defined in the Grant Notice) to permit you to satisfy the  Withholding Obligation and that the Withholding Obligation shall be satisfied pursuant to this  Section 13(c) to the fullest extent not otherwise satisfied pursuant to the provisions of Section  13(d) hereof and (ii) further acknowledge and agree to the following provisions:  (i) You hereby irrevocably appoint E*TRADE, or such other registered  broker-dealer that is a member of the Financial Industry Regulatory Authority as the Company  may select, as your agent (the “Agent”), and you authorize and direct the Agent to:  (1) Sell on the open market at the then prevailing market  price(s), on your behalf, as soon as practicable on or after the date on which the Shares are  delivered to you pursuant to Section 8 hereof in connection with the vesting of the French- Qualified RSUs, the number (rounded up to the next whole number) of Shares sufficient to  generate proceeds to cover (A) the satisfaction of the Withholding Obligation arising from the  vesting of those French-Qualified RSUs and the related issuance of Shares to you that is not  

 

     9.     8-15-2022        otherwise satisfied pursuant to Section 13(d) hereof and (B) all applicable fees and commissions  due to, or required to be collected by, the Agent with respect thereto;   (2)  Remit directly to the Company and/or any Affiliate the  proceeds necessary to satisfy the Withholding Obligation;  (3) Retain the amount required to cover all applicable fees and  commissions due to, or required to be collected by, the Agent, relating directly to the sale of the  Shares referred to in clause (1) above; and  (4) Remit any remaining funds to you.   (ii) You acknowledge that your election to Sell to Cover and the  corresponding authorization and instruction to the Agent set forth in this Section 13(c) to sell  Shares to satisfy the Withholding Obligation is intended to comply with the requirements of Rule  10b5-1(c)(1) under the Exchange Act or other applicable securities laws and to be interpreted to  comply with the requirements of Rule 10b5-1(c) under the Exchange Act or other applicable  securities laws (your election to Sell to Cover and the provisions of this Section 13(c), collectively,  the “10b5-1 Plan”). You acknowledge that by accepting this Award, you are adopting the 10b5-1  Plan to permit you to satisfy the Withholding Obligation. You hereby authorize the Company and  the Agent to cooperate and communicate with one another to determine the number of Shares that  must be sold pursuant to Section 13(c)(i) to satisfy your obligations hereunder.  (iii) You acknowledge that the Agent is under no obligation to arrange  for the sale of Shares at any particular price under this 10b5-1 Plan and that the Agent may effect  sales as provided in this 10b5-1 Plan in one or more sales and that the average price for executions  resulting from bunched orders may be assigned to your account.  You further acknowledge that  you will be responsible for all brokerage fees and other costs of sale associated with this 10b5-1  Plan, and you agree to indemnify and hold the Company harmless from any losses, costs, damages,  or expenses relating to any such sale.  In addition, you acknowledge that it may not be possible to  sell Shares as provided for in this 10b5-1 Plan due to (i) a legal or contractual restriction applicable  to you or the Agent, (ii) a market disruption, (iii) a sale effected pursuant to this 10b5-1 Plan that  would not comply (or in the reasonable opinion of the Agent’s counsel is likely not to comply)  with the Securities Act or other applicable securities laws, (iv) the Company’s determination that  sales may not be effected under this 10b5-1 Plan or (v) rules governing order execution priority on  the national exchange where the Shares may be traded.  In the event of the Agent’s inability to sell  Shares, you will continue to be responsible for the timely payment to the Company of all federal,  state, local and foreign taxes that are required by applicable laws and regulations to be withheld,  including but not limited to those amounts specified in Section 13(c)(i)(1) above.  (iv) You acknowledge that regardless of any other term or condition of  this 10b5-1 Plan, the Agent will not be liable to you for (A) special, indirect, punitive, exemplary,  or consequential damages, or incidental losses or damages of any kind, or (B) any failure to  perform or for any delay in performance that results from a cause or circumstance that is beyond  its reasonable control.  

 

     10.     8-15-2022        (v) You hereby agree to execute and deliver to the Agent any other  agreements or documents as the Agent reasonably deems necessary or appropriate to carry out the  purposes and intent of this 10b5-1 Plan.  The Agent is a third-party beneficiary of this Section  13(c) and the terms of this 10b5-1 Plan.  (vi) Your election to Sell to Cover and to enter into this 10b5-1 Plan is  irrevocable. Upon acceptance of the Award, you have elected to Sell to Cover and to enter into  this 10b5-1 Plan, and you acknowledge that you may not change this election at any time in the  future. This 10b5-1 Plan shall terminate not later than the date on which the Withholding  Obligation arising from the vesting of your French-Qualified RSUs and the related issuance of  Shares has been satisfied.  (d) Alternatively, or in addition to or in combination with the Sell to Cover  provided for under Section 13(c), you authorize the Company, at its discretion, to satisfy the  Withholding Obligation by the following means (or by a combination of the following means):  (i) Requiring you to pay to the Company any portion of the  Withholding Obligation in cash;  (ii) Withholding from any compensation otherwise payable to you by  the Company; and/or  (iii) Withholding Shares from the Shares issued or otherwise issuable to  you in connection with the Award with a Fair Market Value (measured as of the date Shares are  issued pursuant to Section 8) equal to the amount of the Withholding Obligation.    (e) Unless the Withholding Obligation of the Company and/or any Affiliate are  satisfied, the Company shall have no obligation to deliver to you any Shares.  (f) In the event the Withholding Obligation of the Company arises prior to the  delivery to you of Shares or it is determined after the delivery of Shares to you that the amount of  the Withholding Obligation was greater than the amount withheld by the Company, you agree to  indemnify and hold the Company harmless from any failure by the Company to withhold the  proper amount.  14. NO ADVICE REGARDING GRANT.  The Company is not providing any tax, legal or  financial advice, nor is the Company making any recommendations regarding your participation  in the Plan, or your acquisition or sale of the underlying Shares.  You are hereby advised to consult  with your own personal tax, financial and/or legal advisors regarding the consequences of  accepting this Award and by signing the Grant Notice, you have agreed that you have done so or  knowingly and voluntarily declined to do so.  15. UNSECURED OBLIGATION.  Your Award is unfunded, and as a holder of a vested  Award, you shall be considered an unsecured creditor of the Company with respect to the  Company’s obligation, if any, to issue Shares pursuant to this Agreement.  You shall not have  voting or any other rights as a stockholder of the Company with respect to the Shares to be issued  

 

     11.     8-15-2022        pursuant to this Agreement until such Shares are issued to you pursuant to Section 8 of this  Agreement.   Upon such issuance, you will obtain full voting and other rights as a stockholder of  the Company.  Nothing contained in this Agreement, and no action taken pursuant to its provisions,  shall create or be construed to create a trust of any kind or a fiduciary relationship between you  and the Company or any other person.  16. OTHER DOCUMENTS.  You hereby acknowledge receipt or the right to receive a  document providing the information required by Rule 428(b)(1) promulgated under the Securities  Act, which includes the Plan prospectus.  In addition, you acknowledge receipt of the Company’s  policy on trading in Company securities permitting employees to sell Shares only during certain  “window” periods and the Company’s insider trading policy, in effect from time to time.    17. NOTICES; ELECTRONIC DELIVERY AND ACCEPTANCE.  Any notices provided for  in your Award or the Plan shall be given in writing and shall be deemed effectively given upon  receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit in  the United States mail, postage prepaid, addressed to you at the last address you provided to the  Company.  Notwithstanding the foregoing, the Company may, in its sole discretion, decide to  deliver any documents related to participation in the Plan and this Award by electronic means or  to request your consent to participate in the Plan by electronic means.  You hereby consent to  receive such documents by electronic delivery and, if requested, to agree to participate in the Plan  through an on-line or electronic system established and maintained by the Company, the Agent or  another third party designated by the Company and agree notice shall be provided upon posting to  your electronic account held by the Company, the Agent or another third party designated by the  Company.  You hereby acknowledge that delivery, execution and acceptance of this or any other  such documents by electronic means constitutes valid and effective delivery, execution and  acceptance and shall be legally effective to create a valid and binding agreement.  18. CLAWBACK/RECOUPMENT.  The Award will be subject to recoupment, rescission,  payback, cancelation or other action, in each case, in accordance with (i) any clawback policy  adopted by the Company (whether such policy is adopted on or after the date of this Agreement or  required under applicable law) providing for the recovery of Awards, Shares, proceeds, or  payments to you in the event of fraud or as required by applicable law or governance considerations  or in other similar circumstances and (ii) any such other clawback, recovery or recoupment  provisions set forth in an individual written agreement between you and the Company.  No  recovery of compensation under such a clawback policy will be an event giving rise to your right  to resign for “good reason” or “constructive termination” (or similar term) under any plan of, or  agreement with, the Company.  19. RESTRICTIONS ON THE SALE OF SHARES.  (a) Minimum Mandatory Holding Period.  You will not be permitted to sell or  transfer any Shares issued at settlement of the French-Qualified RSUs before the end of a minimum  mandatory holding period, to the extent applicable to the Shares underlying the French-Qualified  RSUs under Section L. 225-197-1 of the French Commercial Code, as amended, or the French Tax  Code or the French Social Security Code, as amended, to benefit from the special tax and social  

 

     12.     8-15-2022        security regime in France; provided, however, that such minimum mandatory holding period, if  any, shall not apply to Shares subject to the French-Qualified RSUs issued to your heirs pursuant  to Section 3 hereof or to Shares subject to the French-Qualified RSUs after a Termination of  Employment due to Disability (as defined under the French RSU Sub-Plan) pursuant to Section 3  hereof. The minimum mandatory holding period is currently two years from the date of grant.   (b) Closed Period. The Shares issued following any vesting date may not be  sold during a Closed Period, to the extent applicable under French law; provided, however, that  such Closed Period restriction shall not apply to Shares subject to the French-Qualified RSUs  issued to your heirs pursuant to Section 3 hereof or to Shares subject to the French-Qualified RSUs  issued to you after a Termination of Employment due to Disability (as defined under the French  RSU Sub-Plan) pursuant to Section 3 hereof.   (c) Holding Period for Managing Corporate Officers. If you qualify as a  managing corporate officer under French law and have been granted Awards in this capacity  (“mandataires sociaux,” i.e. Président du Conseil d’Administration, Directeur Général, Directeur  Général Délégué, Membre du Directoire, Gérant de Sociétés par actions), you may be subject to  shareholding restrictions under French law and may not sell 20% of the Shares upon settlement  until you cease to serve as a managing corporate officer.  (d) Compliance with Transfer Restrictions on Shares.  To ensure compliance  with restrictions on the transfer of Shares described in this Section 19, the Company may require  that the Shares be held with a brokerage firm or other agent designated by the Company (or  according to any procedure implemented by the Company) until such Shares are sold.   20. MISCELLANEOUS.  (a) The rights and obligations of the Company under your Award shall be  transferable by the Company to any one or more persons or entities, and all covenants and  agreements hereunder shall inure to the benefit of, and be enforceable by, the Company’s  successors and assigns.   (b) You agree upon request to execute any further documents or instruments  necessary or desirable in the sole determination of the Company to carry out the purposes or intent  of your Award.  (c) You acknowledge and agree that you have reviewed your Award in its  entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting  your Award, and fully understand all provisions of your Award.  (d) You acknowledge and agree that the Company shall not be liable for any  exchange rate fluctuation between your local currency and the United States Dollar that may affect  the value of your Award or of any amounts due to you pursuant to the settlement of the Award or  the subsequent sale of any Shares acquired upon settlement.  

 

     13.     8-15-2022        (e) This Agreement shall be subject to all applicable laws, rules, and  regulations, and to such approvals by any governmental agencies or national securities exchanges  as may be required.  (f) All obligations of the Company under the Plan and this Agreement shall be  binding on any successor to the Company, whether the existence of such successor is the result of  a direct or indirect purchase, merger, consolidation, or otherwise, of all or substantially all of the  business and/or assets of the Company.  21. GOVERNING PLAN DOCUMENT.  Your Award is subject to all the provisions of the  Plan, the provisions of which are hereby made a part of your Award, and is further subject to all  interpretations, amendments, rules and regulations which may from time to time be promulgated  and adopted pursuant to the Plan.  Except as expressly provided herein, in the event of any conflict  between the provisions of your Award and those of the Plan, the provisions of the Plan shall  control.   22. ENTIRE AGREEMENT.  The Plan, this Agreement and the Grant Notice constitute  the entire agreement of the parties with respect to the subject matter hereof and supersede in their  entirety all prior undertakings and agreements of the Company and you with respect to the subject  matter hereof, with the exception of any arrangement that would provide for vesting acceleration  of this Award upon the terms and conditions set forth therein.    23. SEVERABILITY.  If all or any part of this Agreement or the Plan is declared by any  court or governmental authority to be unlawful or invalid, such unlawfulness or invalidity shall  not invalidate any portion of this Agreement or the Plan not declared to be unlawful or invalid.  Any Section of this Agreement (or part of such a Section) so declared to be unlawful or invalid  shall, if possible, be construed in a manner which will give effect to the terms of such Section or  part of a Section to the fullest extent possible while remaining lawful and valid.  24. DATA PRIVACY.  To participate in the Plan, you will need to review the  information provided in this Section and, where applicable, declare your consent to the  processing of personal data by the Company and third parties noted below.   (a) EEA+ Controller and Representative.  If you are based in the European  Union (“EU”), the European Economic Area, Switzerland or, if and when the United Kingdom  leaves the European Union, the United Kingdom (collectively “EEA+”), you should note that  the Company, with its registered address at 21823 30th Drive SE Bothell, Washington 98021,  United States of America, is the controller responsible for the processing of your personal data  in connection with the Agreement and the Plan. The Company’s representative in the EU is  Seagen Netherlands B.V., located at Evert van de Beekstraat 1, -140 1118CL Schiphol,  Netherlands with office phone: +31 207 99 15 60.  (b) Data Collection and Usage. In connection with the administration of the  Plan, the Company collects, processes, uses and transfers certain personally-identifiable  information about you, which may include your name, home address and telephone number,  

 

     14.     8-15-2022        email address, date of birth, social insurance, passport number or other identification number,  salary, nationality, job title, details of all Awards or any other entitlement to Shares awarded,  canceled, exercised, settled, vested, unvested or outstanding in your favor and additional similar  or related data, which the Company receives from you or the entity that employs you (“Personal  Data”).  Specifically, the Company collects, processes and uses Personal Data for the purposes  of performing its contractual obligations under this Agreement, implementing, administering  and managing your participation in the Plan and facilitating compliance with applicable tax  and securities law.   If you are based in the EEA+, the legal basis, where required, for the processing of Personal  Data by the Company is the necessity for the Company to (i) perform its contractual obligations  under this Agreement, (ii) comply with legal obligations established in the EEA+, and/or (iii)  pursue the legitimate interest of complying with legal obligations established outside of the  EEA+.    (c) Stock Plan Administration Service Providers. The Company transfers  Personal Data to E*TRADE Corporate Financial Services, Inc., and E*TRADE Securities LLC  (collectively, “E*TRADE”) and certain of its affiliated companies and successors (the “Stock  Plan Provider”), an independent service provider, which assists the Company with the  implementation, administration and management of the Plan, including providing ancillary  services related to stock plan administration.  The Company may select a different service  provider or additional service providers and share Personal Data with such other provider  serving in a similar manner.  The processing of Personal Data will take place through both  electronic and non-electronic means. Personal Data will only be accessible by those individuals  requiring access to it for purposes of implementing, administering and operating the Plan,  including providing ancillary services related to stock plan administration.  You may be asked  to agree on separate terms and data processing practices with the Stock Plan Provider, with  such agreement being a condition to the ability to participate in the Plan.  (d) International Data Transfers. The Company and the Stock Plan Provider  are based in the United States. The country where you live may have different data privacy laws  and protections than the United States. In particular, the United States does not have the same  level of protections for personal data as countries in the EEA+.  The European Commission  requires U.S. companies to protect personal data leaving the EEA+ by implementing safeguards  such as the Standard Contractual Clauses adopted by the EU Commission.   If you are based in the EEA+, Personal Data will be transferred from the EEA+ to the Company  and onward from the Company to the Stock Plan Provider, or if applicable, another service  provider, based on the EU Standard Contractual Clauses. You may request a copy of the  Standard Contractual Clauses by contacting dataprotection@seagen.com.   (e) Data Retention. The Company will use Personal Data only as long as  necessary to implement, administer and manage your participation in the Plan, or as required  to comply with legal or regulatory obligations, including tax and securities laws.  When the  

 

     15.     8-15-2022        Company no longer needs Personal Data for any of these purposes, the Company will remove it  from its systems.   (f) Voluntariness and Consequences of Consent Denial or Withdrawal.  Participation in the Plan is voluntary and you are providing the consents herein on a purely  voluntary basis. You may withdraw your consent at any time, with future effect and for any or  no reason. If you do not consent, or if you later seek to withdraw your consent, your salary from  or employment or service relationship with your employer will not be affected. The only  consequence of denying or withdrawing consent is that the Company would not be able to grant  Awards to you under the Plan or administer or maintain your participation in the Plan. If you  withdraw your consent, the Company will stop processing your Personal Data for the purposes  stated in Section (b) above unless to the extent necessary to comply with tax or other legal  obligations in connection with Awards granted before you withdrew your consent.  (g) Data Subject Rights. You may have a number of rights under data privacy  laws in your jurisdiction.  Subject to the conditions set out in the applicable law and depending  on where you are based, such rights may include the right to (i) request access to, or copies of,  Personal Data processed by the Company, (ii) rectification of incorrect Personal Data, (iii)  deletion of Personal Data, (iv) restrict the processing of Personal Data, (v) object to the  processing of Personal Data for legitimate interests, (vi) portability of Personal Data, (vii) lodge  complaints with competent authorities in your jurisdiction, and/or to (viii) receive a list with the  names and addresses of any potential recipients of Personal Data. To receive clarification  regarding these rights or to exercise these rights, you can contact dataprotection@seagen.com.  (h) Necessary Disclosure of Personal Data. You understand that providing  the Company with Personal Data is necessary for the performance of this Agreement and that  your refusal to provide Personal Data would make it impossible for the Company to perform its  contractual obligations and would affect your ability to participate in the Plan.  25. INSIDER TRADING RESTRICTIONS/MARKET ABUSE LAWS.  You acknowledge that,  depending on your country, you may be subject to insider trading restrictions and/or market abuse  laws, which may affect your ability to acquire or sell the Shares or rights to the Shares under the  Plan during such times as you are considered to have “inside information” regarding the Company  (as defined by the laws in your country).  Any restrictions under these laws or regulations are  separate from and in addition to any restrictions that may be imposed under any applicable  Company insider trading policy.  You acknowledge that it is your responsibility to comply with  any applicable restrictions, and you are advised to speak to your personal advisor on this matter.  26. FOREIGN ASSET/ACCOUNT AND TAX REPORTING, EXCHANGE CONTROLS.  If you  hold cash or Shares outside of France or maintain a foreign bank or brokerage account (including  accounts that were opened and closed during the tax year), you are required to report such assets  and accounts to the French tax authorities on an annual basis on a specified form together with  your income tax return.  Failure to complete this reporting can trigger significant penalties.  

 

     16.     8-15-2022        27. WAIVER.  You acknowledge that a waiver by the Company of a breach of any  provision of this Agreement shall not operate or be construed as a waiver of any other provision  of this Agreement, or of any subsequent breach of this Agreement.  28. LANGUAGE. By accepting this Award, you confirm having read and understood the  Plan and the Agreement which were provided in the English language.  You accept the terms of  those documents accordingly.    En acceptant l’attribution, vous confirmez avoir lu et compris le Plan et ce Contrat, qui  ont été communiqués en langue anglaise.  Vous acceptez les termes de ces documents en  connaissance de cause.  29. GOVERNING LAW/VENUE.  The interpretation, performance and enforcement of  this Agreement will be governed by the law of the State of Delaware without regard to that state’s  conflicts of laws rules.  For purposes of any action, lawsuit or other proceedings brought due to  your participation in the Plan, relating to it, or arising from it, you hereby submit to and consent to  the sole and exclusive jurisdiction of the United States District Court for the Southern District of  New York (or should such court lack jurisdiction to hear such action, suit or proceeding, in a New  York state court in the County of New York), and no other courts, where this Award is granted  and/or to be performed.  30. IMPOSITION OF OTHER REQUIREMENTS.  The Company reserves the right to  impose other requirements on your participation in the Plan, and on any Shares acquired under the  Plan, to the extent the Company determines it is necessary or advisable for legal or administrative  reasons, and to require you to sign any additional agreements or undertakings that may be  necessary to accomplish the foregoing.  31. AMENDMENT.  This Agreement may not be modified, amended or terminated  except by an instrument in writing, signed by you and by a duly authorized representative of the  Company. Notwithstanding the foregoing, this Agreement may be amended solely by the  Administrator by a writing which specifically states that it is amending this Agreement, so long as  a copy of such amendment is delivered to you, and provided that no such amendment materially  adversely affecting your rights hereunder may be made without your written consent, except as  otherwise provided in the Plan. Without limiting the foregoing, the Administrator reserves the right  to change, by written notice to you and without your prior written consent, the provisions of this  Agreement in any way it may deem necessary or advisable to carry out the purpose of the grant to  facilitate compliance with applicable laws or regulations or any future law, regulation, ruling, or  judicial decision.Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential.

License And Distribution Agreement

This License and Distribution Agreement (this “Agreement”) is made on September 15, 2022 (the “Effective Date”) by and between Axim Biotechnologies, Inc. (“Licensor”), a Nevada corporation, and Verséa Ophthalmics, LLC, a Delaware limited liability company (“Licensee”).

RECITALS

WHEREAS, Licensor develops, manufactures, distributes, and markets rapid, POC tests and owns and maintains specific exclusive intellectual property around a universal digital multi-use reader for its POC Products that allow for the qualitative, semi-quantitative, and quantitative analysis of lateral flow test strips;

WHEREAS, Licensor has developed and markets an ocular tear based diagnostic test that detects i) lactoferrin for the detection of aqueous deficient dry eye, and ii) total IgE for the confirmation of allergic conjunctivitis;

WHEREAS, Licensor has a proprietary, quantitative MMP-9 ocular tear based diagnostic test and anticipates entering U.S. FDA pivotal clinical trials in late 2022 or early 2023;

WHEREAS, Licensee is an ophthalmic distribution company with exclusive rights to amniotic membrane biologic therapies;

WHEREAS, Licensor and Licensee desire to enter into a commercial agreement to accelerate the commercialization of both the existing Axim POC tear-based tests and to receive an option to the future MMP-9 test based on the synergies of the product lines and, specifically, to grant to Licensee the right and license to sell and distribute the products, as set forth on Schedule A attached hereto (the “Products”); and

WHEREAS, Licensee wishes to sell and distribute the Products under the terms and conditions set forth in this Agreement.

NOW, THEREFORE, in consideration of the mutual promises set forth herein, Licensee and Licensor hereby agrees as follows:

1.EXCLUSIVE LICENSE GRANT 

1.1Product and Brand License 

Licensor hereby grants to Licensee an exclusive license to use, market, sell, distribute and otherwise commercially exploit, the Products in the territory set forth on Schedule B (the “Territory”) subject to the terms and conditions hereafter set forth in this Agreement.  The Licensee shall sell, distribute and/or market the Products, and shall provide customer and administrative support in respect of the Products.  Further, Licensee shall provide tracing reports in respect of customers, in the event of recall. Licensor will provide an internal system for tracking components included in each lot.  Licensee shall be permitted, in the reasonable discretion of Licensor, to utilize sub-distributors (“Sub-Distributors”) for the distribution and marketing of the Products.

Licensor shall retain exclusive control of the manufacture and production of the Products and all intellectual and industrial property rights arising from or related to the Products.  For the avoidance of doubt, Licensor shall own all usability and clinical data and have exclusive rights to all know-how relating to any Product, and Licensee shall not supply Products for third party clinical evaluation without the prior written consent of Licensor.  In its sole discretion, Licensor may share with Licensee data for use in market conditioning and promotional activities.

Licensor also hereby grants Licensee the right and license in the Territory to use any and all of the Licensor’s brands associated with the Product (the “Licensor Brand”), subject to the brand usage guidelines applicable thereto as provided by Licensor to Licensee from time-to-time.

1.2Term 

This Agreement is effective upon the Effective Date.  This Agreement will last for an initial term of five (5) years from the Effective Date (the “Initial Term”).  Thereafter, this Agreement will renew automatically for sequential two (2) year terms (each, a “Renewal Term” and, together with the Initial Term, the “Term”) unless either party, within ninety (90) days prior to the end of the Initial Term or the applicable Renewal Term, as the case may be, notifies the other party in writing of its intent to terminate this Agreement.  During the Term, and for a one (1) year period thereafter, Licensee and its Sub-Distributors shall not sell, distribute, and /or market within the Territory any product testing for the same FDA 510k cleared analytes as the Products, including IgE, lactoferrin, or MMP-9.

1.3Consideration 

Consideration for the license granted hereunder shall be as set forth on Schedule B-1 hereof.  Following the Initial Order, as set forth on Schedule B-2 hereof, Licensee shall purchase from Licensor, and Licensor shall supply to Licensee, such quantities of the Products as Licensee orders pursuant to this Agreement, with a noncancelable Purchase Order inclusive of a down payment of fifty percent (50%) on order and fifty percent (50%) net-30 payment after delivery at Licensor’s facility.

1.4Manufacture, Purchase and Supply of Products 

(a)Upon the terms and subject to the conditions contained herein, Licensee shall purchase the Products from Licensor or its authorized third-party manufacturers pursuant to purchase orders (each, a “Purchase Order”) which shall set forth the applicable Products that Licensee desires to purchase, the quantity thereof and such other information as required for Licensor to fulfill the applicable Purchase Order.  Licensor shall deliver the Products to Licensee on the delivery dates specified in each applicable Purchase Order.  If any Product set forth in any Purchase Order is not in stock, Licensor will promptly notify Licensee in writing of such unavailability; and provide Licensee with an estimate of the date by which the applicable Product will be available. 

(b)Licensee shall promptly inspect all Products upon delivery.  All Products shall be deemed to be free of defects, shortages or nonconformities, unless Licensee notifies Licensor of such defects, shortages, or nonconformities in writing within ten (10) business days after the date of delivery.  If Licensee notifies Licensor of any defect, shortage or nonconformity within such period, Licensor shall promptly correct the applicable defect, shortage, or nonconformity. 

1.5Pricing; Annual Sales Minimum. 

The parties agree that the pricing and annual sales minimum for the Products shall be as set forth on Schedule B-3 hereof.

1.6Branding and Marketing 

As long as Licensee maintains exclusivity in accordance with Section 1.2 hereof, Licensor grants Licensee rights to private label Products in Licensee’s sole discretion during the Term.

1.7Payment Terms. 

(a)All payments by Licensee to Licensor hereunder shall be in U.S. Dollars by wire or electronic transfer to the account below: 

- 2 -

(i)ACH or wire transfer to the following Licensor account: 

1)Account Name:Axim Biotechnologies, Inc. 

2)Account Number:[                             ] 

3)Bank Name:[                             ] 

4)Bank Address:[                             ] 

5)ABA Routing Number:[                             ] 

6)Swift Code: `[                             ] 

2.LICENSEE’S REPRESENTATIONS AND WARRANTIES 

The Licensee hereby represents and warrants to the Licensor that:

2.1Organization 

The Licensee is a limited liability company duly formed, validly existing, and in good standing under the laws of the State of Delaware.

2.2Authority; No Violation. 

The Licensee has the power and authority and the legal right to enter into this Agreement and perform its obligations hereunder, and (has taken all necessary limited liability company action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of the Licensee and constitutes a legal, valid and binding obligation of the Licensee and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other similar laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is considered in a proceeding at law or equity. The execution and delivery of this Agreement and performance of the Licensee’s obligations contemplated hereby will not constitute a violation or default under (i) any applicable law, (ii) any term or provision of the Certificate of Formation or operating agreement of the Licensee or (iii) of any contract, commitment, indenture, other agreement or order to which the Licensee is a party or by which the Licensee is bound.

2.3Litigation. 

There are no actions, proceedings, or investigations pending or, to the knowledge of the Licensee, threatened against the Licensee, and the Licensee knows or has any reason to know of any basis for any such action, proceedings, or investigation.

2.4Sub-Distributors. 

Any Sub-Distributor shall be bound by terms and conditions substantially similar to those contained in this Agreement.  Upon request by Licensor, Licensee shall immediately furnish to Licensor any agreement with a Sub-Distributor in respect of the Products.  Any agreement with a Sub-Distributor in respect of the Products shall terminate immediately upon the termination of this Agreement.

- 3 -

 

2.5Compliance with Laws. 

The Licensee is in material compliance with all applicable laws, regulations, and orders and the performance of its rights and obligations, including those performed by any Sub-Distributor, shall be in material compliance with all applicable laws, regulations, and orders, including those in respect of anti-corruption laws.  Without limiting the generality of the foregoing, the Licensee further represents, warrants, and covenants that: (a) it has been at all times and shall continue to be in compliance with all potentially applicable anti-bribery and anti-corruption laws, including the U.S. Foreign Corrupt Practices Act of 1977 and the Federal Anti-Kickback Statute (42 U.S. C. § 1320a-7b(b)); (b) no bribes, payments, kickbacks, gifts, hospitality, donations, loans, or anything of value have been or shall be made or received, offered, promised, or authorized, directly or indirectly, to improperly influence any act or decision of any third party, induce any third party to do or omit to do any act in violation of any third party’s lawful duties, or secure any improper advantage; and (c) it has implemented a compliance and ethics program (including obligations to train contractors and sub-contractors interacting with officials of any governmental authority in connection with this Agreement) designed to prevent and detect violations of applicable anti-bribery and anti-corruption laws through its operations and the operations of its Affiliates, contractors and sub-contractors that have responsibility for commercialization or manufacturing of the Products, payments or services pursuant to this Agreement, and covenants that it will maintain and enforce such compliance and ethics program at all times. During the term of this Agreement, neither the Licensee, nor any of its subsidiaries or affiliates, officers, directors, employees, agents, or any-one acting on its or their behalf shall engage in any such Prohibited Actions.

3.LICENSOR’S REPRESENTATION AND WARRANTIES 

Licensor represents and warrants to Licensee that:

3.1The Licensor is a corporation duly organized, validly existing, and in good standing under the laws of the State of Nevada. 

3.2The Licensor has the power and authority and the legal right to enter into this Agreement and perform its obligations hereunder, and (has taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. This Agreement has been duly executed and delivered on behalf of the Licensee and constitutes a legal, valid and binding obligation of the Licensor and is enforceable against it in accordance with its terms, subject to the effects of bankruptcy, insolvency or other similar laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity, whether enforceability is considered in a proceeding at law or equity. The execution and delivery of this Agreement and performance of the Licensor’s obligations contemplated hereby will not constitute a violation or default under (i) any applicable law, (ii) any term or provision of the Certificate of Incorporation or bylaws of the Licensor or (iii) of any contract, commitment, indenture, other agreement or order to which the Licensor is a party or by which the Licensee is bound 

3.3The Licensor is in material compliance with all applicable laws, regulations, and orders and the performance of its rights and obligations hereunder shall be in material compliance with all applicable laws, regulations, and orders, including those in respect of anti-corruption laws.  Without limiting the generality of the foregoing, the Licensor further represents, warrants, and covenants that: (a) it has been at all times and shall continue to be in compliance with all potentially applicable anti-bribery and anti-corruption laws, including the U.S. Foreign Corrupt Practices Act of 1977 and the Federal Anti-Kickback Statute (42 U.S. C. § 1320a-7b(b)); (b) no bribes, payments, kickbacks, gifts, hospitality, donations, loans, or anything of value have been or shall be made or received, offered, promised, or authorized, directly or indirectly, to improperly influence any act or decision of any third party, induce any third party to do or omit to do any act in violation of any third party’s lawful duties, or secure any improper advantage; and (c) it has implemented a compliance and ethics program (including obligations to train contractors and sub-contractors interacting with officials of any governmental authority in connection with this Agreement) designed to prevent and detect violations of applicable anti-bribery and anti- 

- 4 -

corruption laws through its operations and the operations of its Affiliates, contractors and sub-contractors that have responsibility for commercialization or manufacturing of the Products, payments or services pursuant to this Agreement, and covenants that it will maintain and enforce such compliance and ethics program at all times

3.4Licensor is the owner, or has the necessary rights, in and of the Products and the rights to use, market and sell the Products and to grant the license granted hereunder to Licensee. 

3.5Licensor has not granted any right or license to the Products that would conflict with any term under this Agreement. 

3.6Licensor shall not enter any Agreement with any third party which would affect Licensee’s rights under this Agreement, or bind Licensee to any third party, without Licensee’s prior written consent. 

3.7Licensee’s use of the Products and their respective brands as authorized by this Agreement will not infringe any existing copyright, trade secret, patent or trademark right of any third party. 

3.8Licensor will be solely responsible for seeking a CLIA waived status including the cost associated with any new regulatory clinical trials, useability trials, or laboratory studies.   Notwithstanding the foregoing, Licensee will be responsible for fifty percent (50%) of costs entailed in conducting clinical trials of MMP-9 for the purposes of seeking FDA regulatory clearance.  

3.9Promptly upon receipt thereof, the Licensor will forward to the Licensee any distribution requests in respect of the Products that it receives. 

3.10Promptly following execution of this Agreement, the Licensor will introduce any historic accounts in respect of the Products to the Licensee. 

4.DUTIES AND OBLIGATIONS OF LICENSEE. 

4.1Sales & Marketing. 

(a)Licensee shall establish and maintain properly trained sales organization and other support personnel as needed for distributing the Products. Licensee shall provide Customer support, services, and assistance as is standard and customary for similar Products.  Licensee is authorized to distribute, sell or use the Product within the Territory only and specifically agrees not to exceed the Territory. 

(b)Licensee will be responsible for its own costs to exhibit at tradeshows or conferences. Licensee may, in its sole discretion, establish and maintain medical advisory boards for the Products at its sole cost.  

(c)Licensee will provide Licensor drafts of any marketing or promotional materials for review prior to release or publication and agrees to incorporate all of Licensor’s requested changes that relate to regulatory compliance and Licensor’s reasonable requests for changes to the materials of any other nature. If the Licensor fails to respond within two (2) business days after being provided with such materials, they shall be deemed to have been approved by the Licensor. 

(d)Licensee shall inform Licensor about the initiation of any scientific study related to the Product within the Territory that is intended to report results in a publication. This includes studies where the Licensee will sell or provide product gratis to the study site. All Clinical study requests should be reviewed with Licensor. Licensee will not knowingly supply Products for third party clinical study evaluation at a discount or gratis, without Licensor reviewing and approving any clinical protocols to be used in the studies. If Licensor agrees to support the 3rd party clinical evaluations that include discounted or free Products, Licensor agrees to pay for these costs. 

- 5 -

(e)Licensee shall promote the Products in a truthful and lawful manner.  Licensee shall make no Product claim other than those contained in the Documentation provided by Licensor to Licensee.  Licensee shall always refer to Licensor as the manufacturer of the Products and may identify itself as a Licensee or exclusive Distributor of the Products in advertising and promotional materials by using the phrase “Distributed by (Licensee’s Name) or “Exclusively Distributed by (Licensee’s Name)”. 

4.2Translations. Licensee shall be responsible for performing in due time and to the standard required by the relevant authority all translations in local language that are compulsory for applying, obtaining, or maintaining all Product registrations and authorizations, in compliance with all local regulations, and with the data and information provided by Licensor. Licensee shall provide Licensor copies of all such translations prior to submitting to any third parties and reimburse Licensor for validation and/or certification of the translation if reasonably required by Licensor for quality or regulatory compliance.  Typically, the package insert is the only Documentation that requires certified translations, but additional Documentation may require a certified translation. Alternatively, Licensee may reimburse Licensor for Licensor having the certified translations prepared. 

4.3Facilities. Licensee shall, at all times, maintain a physical place for the inventory and transport of Products.  Licensee shall maintain suitable, temperature controlled, contamination-free storage facilities for such inventory in accordance with label conditions and all applicable governmental and industry standards. 

4.4CLIA Status. Licensee agrees to pay for ongoing Moderate Complexity CLIA certification third party support until a waiver is granted.  Licensor agrees to provide at its cost, all calibration cassettes, proficiency testing samples, linearity and validation samples and cassettes required to establish a moderately complex laboratory.  In addition, Licensor agrees to receive and process any proficiency reports. 

4.5Reimbursement.  Licensee shall be responsible for arranging and providing any customer and national coverage-related reimbursement, market access and support and Licensee will incur all of these costs including any U.S. new Product requirements for a dedicated Medicare CPT code submission. In the event that issues related to national coverage-related reimbursement develop such that Sales by Licensee are being impacted significantly, the parties agree to re-assess pricing of the Products hereunder. 

4.6Payment of Licensee Costs. Licensee shall pay all costs and expenses that Licensee incurs in carrying out its obligations under this Agreement, and shall have no right of reimbursement thereof from Licensor. Licensee's sole remuneration under this Agreement shall be the profit derived by Licensee from Licensee's use and/or sales of the Products in the Territory. 

4.7Regulatory and Quality. Licensee will be responsible for obtaining all international regulatory approvals and for paying all associated costs.  Licensor will provide support for the approval process. As applicable, the Licensee shall comply with all regulatory and other agencies, including governmental and private, as applicable, in the marketing, distribution, and/or selling of the Products.  Licensor shall provide any approvals, as applicable, to Licensee, that would be beneficial in the efforts of the Licensee. 

(a)Licensee shall appoint one person responsible for regulatory matters, who shall be the direct correspondent of Licensor for all Product registrations, variations, authorizations, and incident reporting matters. 

(b)Licensee shall be responsible to alert Licensor in due time to all changes which may affect the granting or the validity of the Products’ registration and authorizations, or which may create supplementary or new obligations related to the Products’ registrations and authorizations. 

(c)Licensee shall be responsible for all costs associated with international Product registration to the extent that Licensee, in its sole discretion, decides to pursue such international registration.  Licensor agrees to provide regulatory documentation support.  At all times, Licensor will be deemed the manufacturer of record. 

- 6 -

(d)Licensee shall not sell or distribute Products in the Territory until such time as all regulatory/marketing licenses and approvals required by the specific laws and regulations applicable in the Territory have been obtained including device registration where applicable and Licensor has assessed and provided written approval of Licensee’s compliance with the aforementioned standards.  Licensee may provide samples for studies and/or key opinion leader evaluation if authorized in advance by Licensor in writing and local law and regulation prior to the license to sell is obtained. 

(e)Licensee shall receive, communicate with and resolve inquiries from its Customers regarding the use and quality of the Products, and inform Licensor in writing within five (5) days from the day that the Licensee becomes aware of said potential quality issue. Licensee shall notify Licensor in writing immediately of any complaint or report from a healthcare professional, patients or users about suspected incidents related to the device, and legal claim or litigation involving or possibly involving the Products. 

(f)Licensee shall develop, adopt, and maintain all policies and procedures required for Licensee to be fully compliant with any and all relevant laws and regulations applicable in the territory and governing the Licensee’s business. 

(g)Licensee shall distribute Product in the same manner it was received from Licensor and with all of the Product warranties, disclaimers, labeling, Licensor Marks, as defined herein, and Documentation included. Licensee shall not alter, remove, conceal, delete, or modify the warranties, disclaimers, labeling, Licensor Marks, or Documentation. 

(h)To the extent the laws and regulations of a particular Territory require additional or different terms from those set forth in the Product literature provided by Licensor, Licensee shall make appropriate changes to comply with such laws and regulations.  Licensee shall be responsible for ensuring that all Product literature translated or otherwise modified by Licensee is accurate and complete in all respects and otherwise complies with applicable laws and regulations.  Licensee shall notify Licensor of any material changes to the Product literature and obtain Licensor’ prior approval (not to be unreasonably withheld or delayed) before incorporating any such changes into the final form of Product literature disseminated by Licensee. 

(i)Licensee shall ensure that it complies with all applicable data protection laws in its collection, use, processing and transfer of any patient data. All information provided by Licensee to Licensor shall be in de-identified form, and therefore shall not enable Licensor to identify individual patients, in particular it shall not contain the name and/or initials, date of birth, and residential or occupational address of patients. 

(j)Licensee shall be responsible, at its expense, for obtaining all Licenses for sale and distribution of the Products in the Territory and the conduct of its business operations in accordance with this Agreement. All such Licenses shall be obtained in Licensor’s name and on Licensor’s behalf, and no activities in connection with obtaining such Licenses shall be initiated by Licensee without Licensor’s prior written approval; provided, however, that if Regulations require that such a License be obtained in Licensee’s name, then Licensee shall notify Licensor in writing of such requirement and shall hold such License in Licensee’s name for the sole benefit of Licensor and for the sole purpose of complying with Licensee’s obligations under this Agreement.  Licensor shall own and otherwise have the exclusive right to use all Licenses if this Agreement expires or is terminated for any reason.  Licensee shall within thirty (30) days after any expiration or termination, and at Licensee’s sole expense, transfer all such Licenses, and all records pertaining thereto, to Licensor. This Section shall survive any expiration or termination of this Agreement. 

(k)If required by applicable law in the Territory, Licensee shall, at its sole cost and expense: 

(i)register as a Licensee of the Products in the Territory and obtain all licenses from all appropriate governmental ministries, agencies and authorities relevant to the Territory in order that Licensee may advertise, promote, market, distribute, store and sell the Products in the Territory; 

- 7 -

(ii)register the Products with all appropriate governmental, regional ministries, agencies and authorities relevant to the Territory; and 

(iii)submit and file a copy of this Agreement and all related documents and instruments with all appropriate governmental ministries, agencies and authorities relevant to the Territory, all in accordance with then prevailing laws, rules and regulations in force in the Territory. 

5.RECORD-KEEPING, CUSTOMER COMPLAINTS, & PRODUCT TRACING OBLIGATIONS. 

5.1Licensee shall maintain complete, accurate, and detailed records of the Customers it ships Products to, the address of such Customers, and the name and number of units of the Products shipped to each such Customers and shall on a calendar quarterly basis deliver such reports to Licensor. 

5.2Licensee shall maintain a quality system capable of strictly complying with all policies and procedures that Licensor establishes with respect to Product lot traceability, Customer complaints, market surveillance activities, product recalls, and related matters. 

5.3Licensee shall maintain all such records for such periods as are required by all applicable laws, but in no event for less than six (6) years. 

5.4Licensee shall comply with all necessary government and regulatory requirements (including guidance issued by regulatory agencies) regarding the importation, marketing, storage, promotion, and distribution of Products in the Territory. These include the laws and regulations of the Territory and specific requirements for traceability, vigilance, and complaint reporting and handling. 

6.TERMINATION. 

6.1Termination by Licensor; Termination by Licensee. 

(a)In addition to any other rights contained in this Agreement, Licensor has the right, in its sole discretion, to terminate this Agreement upon thirty (30) days written notice to the Licensee if the Annual Minimum Sales Commitments set forth on Schedule B-3 hereof are not achieved by Licensee. 

(b)Further, this Agreement may be terminated immediately by Licensor for the following acts or omissions by Licensee: (i) distribution of Products in violation of applicable laws; (ii) misrepresentation in the marketing and distribution of Products; (iii) misbranding of Products; (iv) adulteration of the Products or marks; (v) any action or statement by Licensee in the performance of its obligations hereunder that Licensor reasonably believes to be detrimental to the reputation and goodwill of Licensor; (vi) engaging in practices or making representations to any customer or potential customer that are misleading, incomplete, fraudulent, untrue, or contrary to the terms of this Agreement; or (vii) failure to retrieve Products during Product retrievals or recalls. 

(c)Licensee has the right to terminate this Agreement with 30 days written notice to Licensor i) if Licensor has not submitted a CLIA waiver application to the FDA for Total IgE or Lactoferrin Product within 8 months of the Effective Date of this Agreement or ii) the MMP-9 test does not obtain FDA clearance and CLIA waiver within 3 years of the Effective Date of this Agreement. 

- 8 -

 

6.2Termination by Either Party. 

(a)If the other party becomes insolvent, goes into liquidation, receivership, voluntary or other administration or some similar legal process, or is otherwise in material breach of this Agreement and, in the event of such a breach, after failing to comply with written notice from the other party demanding cure of such breach within ten (10) business days from the date of such written notice, then at any time thereafter (unless the notifying party expressly waives that failure, breach or circumstance in writing) such other party may, by written notice to the breaching party, immediately terminate this Agreement (the date of such notice being the “Termination Date”). 

(b)Either party may terminate this Agreement upon the occurrence of any of the following: (i) the other party fails to pay any undisputed amount due under this Agreement on the due date for payment and remains in default for more than forty-five (45) days; (ii) the other party commits a material breach of any term of this Agreement and (if that breach is remediable) does not remedy that breach within sixty (60) days of written notice or breach or (iii) respect to any Product, if such Product fails to successfully complete development and/or obtain regulatory clearance. 

6.3Disposition of Inventory. 

Upon expiration or termination of this Agreement, whichever occurs first, Licensee shall, within fifteen (15) days, provide Licensor with a written inventory of all Products in its possession with a specification of the portion that is not currently in a saleable condition.  Thereafter, in Licensor’s sole and absolute discretion, Licensor may elect to pursue none, one, or both of the following options:

(i)Licensee may distribute all saleable Products in its inventory for a period of ninety (90) days after such expiration or termination of Agreement, provided, however, that Licensee shall pay or have paid Licensor for all such Products in the manner herein provided; and/or 

(ii)Licensee may elect to purchase against full product price paid by the Licensee for the remaining portion of such saleable inventory, if such Products are not expired, still in their original packaging, and have a remaining shelf life of at least nine (9) months.  Further, Licensee shall destroy all Products that are in an unsaleable condition in accordance with Licensor’s directions and provide to Licensor a certification of such destruction. 

If Licensee has successfully met all of the minimum sales commitments, termination of this Agreement by Licensor under at the sole and absolute discretion of Licensor, Licensor agrees to (1) repurchase product in inventory against full product price paid by Licensee for the remaining portion of such saleable inventory, if such Products are not expired, still in their original packaging, and have a remaining shelf life of at least nine (9)_ months and/or (2) allow Licensee to nonexclusively distribute all saleable Products in its inventory for an additional period of ninety (90) days after such expiration or termination of Agreement, provided, however, that Licensee shall pay or have paid Licensor for all such Products in the manner herein provided.

6.4Survival of Certain Obligations. 

All obligations of the parties that explicitly or by their nature survive the termination of this Agreement shall continue in full force and effect after the termination of this Agreement until they are satisfied or by their nature expire.

- 9 -

 

7.INDEMNIFICATION; LIMITATION OF LIABILITY 

7.1Indemnification of Licensor by Licensee. 

Licensee shall indemnify, defend and hold harmless Licensor and its directors, officers, employees, owners, managers, consultants, representatives, attorneys, accountants and agents (the “Licensor Indemnified Parties”) from and against any claims, suits, actions or demands against one or more of the Licensor Indemnified Parties, and any losses, liabilities, damages, costs and expenses (including reasonable attorneys’ fees and expenses) incurred by one or more of the Licensor Indemnified Parties, arising out of or caused by (a) any breach by Licensee of any representation, warranty, covenant, undertaking or other provision of this Agreement; (b) the sale, marketing, distribution, advertisement or promotion of the Products, or (c) Licensee’s use of the Licensor Brand in a manner not permitted hereunder.  If and whenever Licensor becomes aware of the initiation of any legal proceeding or the occurrence of any event that gives rise to a claim for indemnification under this Section 7.1, Li-censor shall give prompt written notice thereof to Licensee and shall allow Licensee a reasonable opportunity to assume the defense of any such legal proceeding at Licensee’s sole cost, provided that Licensor shall have the right to participate in the defense at its own cost.

7.2Indemnification of Licensee by Licensor. 

Licensor shall indemnify, defend and hold harmless the Licensee and its affiliates and subsidiaries and their respective directors, officers, employees, owners, managers, consultants, representatives, attorneys, accountants and agents (the “Licensee Indemnified Parties”) from and against any claims, suits, actions or demands against one or more of the Licensee Indemnified Parties, and any losses, liabilities, damages, costs and expenses (including reasonable attorneys’ fees and expenses) incurred by one or more of the Licensee Indemnified Parties, arising out of or caused by (a) any breach by Licensor of any representation, warranty, covenant, undertaking or other provision of this Agreement; (b) the design, manufacture and packaging of the Products; or (c) any allegation that the use of the Licensor Brand by Licensee in the Territory in compliance with this Agreement infringes upon the rights of any third party. If and whenever Licensee becomes aware of the initiation of any legal proceeding or the occurrence of any event that gives rise to a claim for indemnification under this Section 7.2, Licensee shall give prompt written notice thereof to Licensor and shall allow Licensor a reasonable opportunity to assume the defense of any such legal proceeding at Licensor’s sole cost, provided that Licensee shall have the right to participate in the defense at its own cost.

7.3Limitation of Liability. 

EXCEPT FOR EACH PARTY’S INDEMNIFICATION AND CONFIDENTIALITY OBLIGATIONS HEREUNDER, TO THE MAXIMUM EXTENT PERMITTED BY LAW, EACH PARTY DISCLAIMS AND WILL HAVE NO OBLIGATION OR LIABILITY TO THE OTHER PARTY FOR ANY TYPE OF INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES ARISING OUT OF ANY BREACH OF WARRANTY OR OTHERWISE UNDER THIS AGREEMENT (WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE OR BREACH OF STATUTORY DUTY) OR OTHERWISE) EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, WHETHER ARISING UNDER THEORY OF CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE.

- 10 -

 

8.MISCELLANEOUS 

8.1Confidentiality. 

Each party acknowledges and agrees that its respective obligation of confidence and its other respective rights and obligations in relation to confidential information that are set out in the Mutual Confidentiality Agreement dated June 29, 2022 (the “NDA”).  The NDA shall apply to the obligations and rights under this Agreement, all of which are deemed to be within the definitions of “Confidential Information” and “Permit-ted Purpose” in the NDA.  The NDA will remain in full force and effect during the Term of this Agreement notwithstanding any expiration or termination of the NDA prior to expiration or termination of this Agreement.  In the event of any conflict between the terms of the NDA and the terms of this Agreement, the terms of this Agreement shall prevail.

8.2Notice. 

All notices, requests, demands, claims, and other communications made under this shall not be effective unless in writing, and shall be deemed to be delivered and received (i) when delivered personally to the recipient, (ii) one business day after being sent to the recipient by reputable overnight courier service (charges prepaid), (iii) four business days after being mailed to the recipient by certified or registered mail, return receipt requested and postage prepaid, or (iv) when successfully delivered to the recipient by electronic mail, or other electronic transmission, provided that such delivery pursuant to this clause (iv) is subsequently confirmed, in each case, using the applicable contact information for such recipient set forth below:

Axim Biotechnologies, Inc.

John Huemoeller

Chief Executive Officer

6191 Cornerstone Ct. E. Suite 114

San Diego, CA 92121

jh@aximbiotech.com

With a copy (which shall not constitute notice) sent contemporaneously to:

Procopio, Cory, Hargreaves & Savitch, LLP

12544 High Bluff Drive, Suite 400

San Diego, CA 92130

Attention: John Cleary, Esq. 

Telephone No.:(619) 515-3221 

E-Mail:john.cleary@procopio.com 

Verséa Holdings, Inc.

Sean Fetcho

Chief Executive Officer

10808 I. Florida Avenue, Tampa FL 33602

sf@versea.com

 

With a copy (which shall not constitute notice) sent contemporaneously to:

Odell Girton Siegel LLC

Attention: Robert Odell 

E-Mail:notices@ogslawllc.com 

- 11 -

 

8.3Dispute Resolution. 

As a precondition to instituting any legal action, any controversy, claim or dispute arising out of or relating to the provisions of this Agreement or the breach, termination or validity thereof (a “Dispute”), each party will, upon written request of the other party making such Dispute, immediately refer the Dispute for resolution to senior executives of each of the parties who have authority to settle the Dispute.  Within ten (10) days after delivery of a written request regarding a Dispute to the receiving party, the receiving party will submit to the other party a written response.  The request and the response will each include (i) a statement of the respective party’s position and a summary of arguments supporting that position, and (ii) the name and title of the senior executive.  The both parties shall attempt in good faith to resolve the Dispute within ten (10) days after delivery of the response.  The parties agree to honor all reasonable requests for information.  All negotiations pursuant to this provision are confidential and will be treated as compromise and settlement negotiations for purposes of applicable rules of evidence.  If the Dispute has not been resolved by negotiation within ten (10) days after the disputing party’s request, the Parties shall refer the matter for arbitration in accordance with Section 8.4.

8.4Arbitration. 

All claims or disputes arising under or out of or with respect to this Agreement that are not resolved between the parties in accordance with Section 8.3, shall be determined by private binding arbitration before a single arbitrator in accordance with the Commercial Rules of the American Arbitration Association (AAA) that are in effect on the date that the notice of a demand for arbitration is given.  If Licensor and Licensee are unable to agree on the identity of a single arbitrator within ten (10) business days after notice of a demand for arbitration is given, then the AAA arbitrator selection rules shall apply.  The seat of any arbitration under this Agreement shall be San Diego, California, and the language of the arbitration shall be English.  Any notice of a demand for arbitration shall include sufficient detail to establish the nature of the dispute (including the claims asserted and the material issues with respect thereto) and shall be delivered to the other party concurrent with delivery to the AAA.  Discovery shall be limited to requests for production of documents and depositions.  No additional formal discovery from the other party (such as interrogatories or requests for admissions) shall be permitted except by mutual consent or as approved by the arbitrator for good cause shown.  The arbitrator’s decision shall be in writing and shall describe in detail the legal reasoning adopted by the arbitrator in support of the decision.  In rendering a decision, the arbitrator shall follow the governing laws of this Agreement as set forth in Section 8.5. The arbitrator’s decision shall be final and binding on the parties, provided, however, that errors of law may be appealed to a court of competent jurisdiction for review.  The arbitrator shall have the power to award attorney’s fees and/or costs to the prevailing party if, in the arbitrator’s judgment, the dispute was not a bona fide dispute or the prevailing party’s position was substantially more compelling than the other party’s position.  Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction over the parties.

8.5Governing Law. 

This Agreement shall be governed by, and construed in accordance with the laws of the State of Delaware, without regard to its conflict of law provisions.

8.6Counterparts. 

This Agreement may be executed simultaneously in several counterparts (including by means of facsimile, .pdf, or other electronic transmission), each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

8.7Exclusivity. 

Unless defined within this Agreement, Licensee has the right to distribute its other products, not defined in the description of Products as stated in Schedule A of this Agreement, in any country, market, or other venue as Licensee desires, unless stated within this Agreement.

- 12 -

8.8Addenda. 

Either party may have reason to add components to this Agreement at any time under the term of the Agreement.  Any agreed upon modifications to this Agreement shall be stated in an addendum to the Agreement and shall be signed by both parties.

8.9Assignment.  

This Agreement and the performance of any duties hereunder may not be assigned, transferred, delegated, sold or otherwise disposed of by a Party other than (a) with the prior written consent of the other Party, or (b) in connection with the sale of all or substantially all of the assets of a Party hereto, or the merger or acquisition of a Party hereto.

8.10Severability. 

In case any one or more of the provisions contained in this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provision of this Agreement but this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein.

8.11Publicity. 

Upon execution of this Agreement, the parties agree to work collaboratively on a press release which must be approved by both parties in writing.  Any public facing Product claims such as on social media or on websites must be approved by Licensor in writing before implementation, which approval will not be unreasonably withheld.

[The signature page follows.]

- 13 -

 

IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the Licensor and the Licensee on the date first above written.

	AXIM BIOTECHNOLOGIES, INC.

	 

	 

	 

	By:

	/s/ John W. Huemoeller II

	 

	Name:

	John W. Huemoeller II

	 

	Title:

	Chief Executive Officer

	 

	 

	 

	 

	 

	 

	 

	VERSÉA OPHTHALMICS, LLC

	 

	 

	 

	By:

	/s/ Sean Fetcho

	 

	Name:

	Sean Fetcho

	 

	Title:

	Chief Executive Officer

	 

- 14 -

 

SCHEDULE A
Products

1.Lactoferrin tear (“Lactoferrin”) test to identify aqueous deficient dry eye 

2.Total IgE Allergy (“IgE”) test to identify allergic conjunctivitis 

3.Quantitative MMP-9 (“MMP-9”) test to identify ocular surface inflammation 

4.Universal Digital Reader for Axim POC tests 

- 15 -

 

SCHEDULE B-1

Consideration

 

	Rights for Lactoferrin and IgE Tests

	License Fee

	Prepayment

	 

	Initial

	 

	 

	Exclusive distribution rights with private label Verséa branding

	$[           ]

	 

	100% for initial 6 months order

 

1.The License Fee of $[         ] is payable within seventy-two (72) hours of execution of this Agreement. 

 

2.In lieu of an initial MMP-9 license fee, Licensee agrees to pay for 50% of the MMP-9 clinical study when both Licensor and Licensee agree to the study protocol estimated to be $[            ] per party.  Licensor will share clinical trial data under confidentiality terms. 

3.Licensor will grant Licensee exclusivity of the Licensor MMP-9 test when the 510k is FDA cleared. 

4.A 100% 6-month prepayment for the MMP-9 test will be required with the first order of MMP-9 tests. 

5.Licensor intends to develop a new test for other biomarkers for the eye care industry. Licensor will grant Licensee a first right of negotiation for exclusivity of any new test related to eye care developed by Licensor that Licensor has proprietary and exclusive rights to out license. 

- 16 -

 

SCHEDULE B-2

Initial Order

1.Minimum Initial Order of [       ] units. 

2.Licensor agrees to provide the readers at cost and any repricing made by the manufacturer, including discounts, will be passed on to Licensee. 

3.Licensee agrees to pay Licensor $[       ] per reader to program, test and repackage (“Set-up Fee”). 

4.Readers initial order [                                              ] 

5.IGE initial test order [                                              ] 

6.Lactoferrin initial test order [                                          ] 

7.Set-up Fee [                                      ] 

8.Initial Order will total $[              ], payable within seventy-two (72) hours of execution of this Agreement minus any prepayments made for the reader. 

9.Licensor will deliver the first [              ] of both tests as Licensee reasonably requests. 

10.Licensee will provide a nonbinding twelve month (12) rolling forecast to Licensor.  Licensee shall be bound and committed and responsible to purchase the initial number of units listed in the first six (6) months of the forecast upon the execution of this Agreement.  Licensee may modify the remaining six (6) months of the forecast by up to 40% of the original volume listed by Licensee from the prior month’s Rolling Forecast. 

11.Licensor will provide the tests purchased for the initial six-month Purchase Order of the forecast within a 90-day lead time from receiving the initial Purchase Order.  Thereafter, by the first of each month, Licensee will provide an updated rolling forecast to Licensor and a Purchase Order.  The Purchase Order will obligate Licensor to provide the tests purchased for each additional monthly purchase of the forecast within a 45-business day lead time from receiving a Purchase Order.  If Licensee requests Licensor to increase its production beyond the rolling forecast, Licensor will make a good faith effort to do so, but will not be obligated to provide such tests within a 45-business day lead time. 

- 17 -

 

SCHEDULE B-3

1.Pricing and Sales Minimums 

2.The Annual Minimum Sales Commitments for each Product are listed below: 

 

	Rights for 
Combined Lactoferrin 
and IgE Tests

	Annual Minimum Sales Commitment (in Units)— Combined

	 

	Year 1

	Year 2

	Year 3

	Year 4

	Year 5

	Exclusive Distribution Rights Without CLIA Waiver

	[     ]

	[    ]

	[    ]

	[    ]

	[    ]

	Exclusive Distribution Rights with CLIA Waiver

	[    ]

	[    ]

	[    ]

	[    ]

	[    ]

 

	Rights for 
MMP-9 Tests

	Annual Minimum Sales Commitment (in Units)

	 

	Year 1

	Year 2

	Year 3

	Year 4

	Year 5

	Exclusive Distribution Rights Without CLIA Waiver

	[    ]

	[    ]

	[    ]

	[    ]

	[    ]

	Exclusive Distribution Rights with CLIA Waiver

	[    ]

	[    ]

	[    ]

	[    ]

	[    ]

 

3.Delivery/Risk of Loss.  The Products shall be delivered, title transferred, and risk of loss shall be passed to Licensee, EX-Works (as defined in INCOTERMS 2010 or any revision thereof) at Licensor’s or its manufacturer’s) shipping dock. Licensee will make all necessary arrangements for shipping (from pickup through customs clearance to delivery) and for the insurance for shipping. 

- 18 -

 

Schedule C

TERRITORY

1.Worldwide / global, within the fields of use of ophthalmology and optometry offices, clinics, schools, and hospital centers, and governmental facilities. 

- 19 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]